OTCPK:CALZ.F

Stock Analysis Report

Executive Summary

Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in the United States, Australia, New Zealand, and internationally.

Snowflake

Fundamentals

Exceptional growth potential with flawless balance sheet.

Risks

  • PolyNovo has significant price volatility in the past 3 months.
  • PolyNovo is covered by less than 3 analysts.

Share Price & News

How has PolyNovo's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

15.9%

CALZ.F

1.1%

US Medical Equipment

-0.5%

US Market


1 Year Return

267.8%

CALZ.F

7.9%

US Medical Equipment

0.9%

US Market

CALZ.F outperformed the Medical Equipment industry which returned 9.7% over the past year.

CALZ.F outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

CALZ.FIndustryMarket
7 Day15.9%1.1%-0.5%
30 Day28.0%3.1%4.8%
90 Day48.1%3.6%2.3%
1 Year267.8%267.8%8.8%7.9%3.1%0.9%
3 Year742.1%742.1%70.9%65.8%45.5%36.0%
5 Year1782.4%1782.4%139.2%112.0%62.5%44.7%

Price Volatility Vs. Market

How volatile is PolyNovo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PolyNovo undervalued based on future cash flows and its price relative to the stock market?

56.74x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for PolyNovo to establish if it is available at moderate discount.

Unable to calculate intrinsic value for PolyNovo to establish if it is available at substantial discount.


Price Based on Earnings

PolyNovo is loss making, we can't compare its value to the US Medical Equipment industry average.

PolyNovo is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for PolyNovo, we can't assess if its growth is good value.


Price Based on Value of Assets

PolyNovo is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is PolyNovo expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

99.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

PolyNovo's revenue is expected to grow significantly at over 20% yearly.

PolyNovo's earnings are expected to grow significantly at over 20% yearly.

PolyNovo's revenue growth is expected to exceed the United States of America market average.

PolyNovo's earnings growth is expected to exceed the United States of America market average.

PolyNovo's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

PolyNovo is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has PolyNovo performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

PolyNovo does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare PolyNovo's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare PolyNovo's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if PolyNovo has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if PolyNovo has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if PolyNovo improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is PolyNovo's financial position?


Financial Position Analysis

PolyNovo is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

PolyNovo's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

PolyNovo has no debt.

PolyNovo has not taken on any debt in the past 5 years.


Balance Sheet

High level of physical assets or inventory.

PolyNovo has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

PolyNovo has sufficient cash runway for 1.4 years based on current free cash flow.

PolyNovo has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 30.7% each year.


Next Steps

Dividend

What is PolyNovo's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate PolyNovo's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate PolyNovo's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as PolyNovo has not reported any payouts.

Unable to verify if PolyNovo's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as PolyNovo has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of PolyNovo's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of PolyNovo's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Paul Brennan 0

4.6yrs

Tenure

AU$315,871

Compensation

Mr. Paul Brennan, MBA, BSc (Nursing), RN, RM has been the Chief Executive Officer of Polynovo Limited since February 13, 2015. Mr. Brennan has been the Marketing Director Australia and New Zealand and Sale ...


CEO Compensation Analysis

Paul's remuneration is lower than average for companies of similar size in United States of America.

Paul's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

0.8yrs

Average Tenure

The average tenure for the PolyNovo management team is less than 2 years, this suggests a new team.


Board Age and Tenure

5.4yrs

Average Tenure

62yo

Average Age

The tenure for the PolyNovo board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyAU$20,73411 Mar 19
Bruce Rathie
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Independent Director
Shares39,597
Max PriceAU$0.52
BuyAU$41,04308 Mar 19
David Williams
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares79,188
Max PriceAU$0.52
BuyAU$29,33830 Nov 18
David Williams
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares68,660
Max PriceAU$0.43
BuyAU$61,19925 Sep 18
David Williams
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares150,000
Max PriceAU$0.41

Ownership Breakdown


Management Team

  • David Smith

    Manufacturing Manager

    • Tenure: 0yrs
    • Compensation: AU$168.95k
  • Tim Moore

    Principal Scientist

    • Tenure: 0yrs
    • Compensation: AU$145.12k
  • Paul Brennan

    Chief Executive Officer

    • Tenure: 4.6yrs
    • Compensation: AU$315.87k
  • Ed Graubart

    Senior Vice President of Americas

    • Tenure: 0yrs
  • Jan-Marcel Gielen

    CFO & Company Secretary

    • Tenure: 0.8yrs
    • Compensation: AU$259.30k
  • Ashok Srinivasan

    Chief Operating Officer

    • Tenure: 0.3yrs
    • Compensation: AU$183.27k
  • Monica Benyk

    HR Manager

    • Tenure: 0yrs

Board Members

  • Bruce Rathie (64yo)

    Non-Executive Independent Director

    • Tenure: 9.6yrs
    • Compensation: AU$56.78k
  • Philip Powell (62yo)

    Non-Executive Director

    • Tenure: 5.3yrs
    • Compensation: AU$56.78k
  • David Williams (55yo)

    Non-Executive Chairman

    • Tenure: 5.5yrs
    • Compensation: AU$89.63k
  • R. Johnston

    Non-Executive Independent Director

    • Tenure: 5.3yrs
    • Compensation: AU$56.78k
  • David McQuillan

    Non-Executive Director

    • Tenure: 7.1yrs
    • Compensation: AU$122.41k
  • Leon Hoare

    Non-Executive Director

    • Tenure: 3.7yrs
    • Compensation: AU$56.78k

Company Information

PolyNovo Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PolyNovo Limited
  • Ticker: CALZ.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$1.481b
  • Listing Market Cap: AU$1.003b
  • Shares outstanding: 661.09m
  • Website: https://www.polynovo.com.au

Number of Employees


Location

  • PolyNovo Limited
  • 320 Lorimer Street
  • Unit 2
  • Port Melbourne
  • Victoria
  • 3207
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CALZ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 1998
PNVASX (Australian Securities Exchange)YesOrdinary SharesAUAUDNov 1998
PNVCHIA (Chi-X Australia)YesOrdinary SharesAUAUDNov 1998
MFJDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 1998

Biography

Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in the United States, Australia, New Zealand, and internationally. The company focuses on the d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 23:45
End of Day Share Price2019/09/23 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.